Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
Authors
Keywords
-
Journal
EXPERT OPINION ON EMERGING DRUGS
Volume 26, Issue 3, Pages 231-243
Publisher
Informa UK Limited
Online
2021-06-28
DOI
10.1080/14728214.2021.1947240
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
- (2021) Thomas A. Wadden et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
- (2021) Melanie Davies et al. LANCET
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
- (2021) Domenica Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
- (2021) Lone B Enebo et al. LANCET
- Clinical management and treatment of obesity in China
- (2021) Qiang Zeng et al. Lancet Diabetes & Endocrinology
- Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
- (2020) Robert F. Kushner et al. Obesity
- 353-OR: Oral Small Molecule GLP-1R Agonist PF-06882961 Robustly Reduces Plasma Glucose and Body Weight after 28 Days in Adults with T2DM
- (2020) ADITI SAXENA et al. DIABETES
- What is on the horizon for type 2 diabetes pharmacotherapy? – An overview of the antidiabetic drug development pipeline
- (2020) Karl Sebastian Johansson et al. Expert Opinion on Drug Discovery
- Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
- (2020) Francis S. Willard et al. JCI Insight
- High‐Dose Glucagon Has Hemodynamic Effects Regardless of Cardiac Beta‐Adrenoceptor Blockade: A Randomized Clinical Trial
- (2020) Kasper M. Petersen et al. Journal of the American Heart Association
- Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity
- (2019) Ryota Usui et al. Journal of Diabetes Investigation
- Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study
- (2019) Natasha C. Bergmann et al. DIABETOLOGIA
- The Dual Amylin and Calcitonin Receptor Agonist KBP-088 Induces Weight Loss and Improves Insulin Sensitivity Superior to Chronic Amylin Therapy
- (2019) Anna Thorsø Larsen et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study
- (2019) Preeshila Behary et al. DIABETES CARE
- Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
- (2019) Richard Pratley et al. LANCET
- Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial
- (2019) Thomas R Pieber et al. Lancet Diabetes & Endocrinology
- Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
- (2019) Helena W. Rodbard et al. DIABETES CARE
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2019) Søren L Kristensen et al. Lancet Diabetes & Endocrinology
- MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
- (2019) Michael A Nauck et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites
- (2018) Caina Li et al. BIOCHEMICAL PHARMACOLOGY
- MEDI0382, a GLP-1-glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomised, phase 1 study
- (2018) Philip D. Ambery et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials
- (2018) Vanita R. Aroda DIABETES OBESITY & METABOLISM
- Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
- (2018) Bo Ahrén et al. DIABETES OBESITY & METABOLISM
- Are peptide conjugates the golden therapy against obesity?
- (2018) S J Brandt et al. JOURNAL OF ENDOCRINOLOGY
- MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
- (2018) Philip Ambery et al. LANCET
- Gut hormone polyagonists for the treatment of type 2 diabetes
- (2018) Sara J. Brandt et al. PEPTIDES
- GLP-1 receptor agonists: differentiation within the class
- (2018) Simeon I Taylor Lancet Diabetes & Endocrinology
- Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
- (2018) M Angelyn Bethel et al. Lancet Diabetes & Endocrinology
- A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials
- (2018) Joachim Tillner et al. DIABETES OBESITY & METABOLISM
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
- (2018) DIABETES CARE
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models
- (2018) Elizabeth A. Killion et al. Science Translational Medicine
- Management of obesity
- (2016) George A Bray et al. LANCET
- The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones
- (2016) Claire L Meek et al. PEPTIDES
- Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors
- (2015) A H Sparre-Ulrich et al. BRITISH JOURNAL OF PHARMACOLOGY
- GLP-1 and Amylin in the Treatment of Obesity
- (2015) T. Jorsal et al. Current Diabetes Reports
- Role of Amylin in Type 1 and Type 2 Diabetes
- (2015) Laura Hieronymus et al. DIABETES EDUCATOR
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucagon Is Essential for Adaptive Thermogenesis in Brown Adipose Tissue
- (2014) Keita Kinoshita et al. ENDOCRINOLOGY
- A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
- (2014) Brian Finan et al. NATURE MEDICINE
- A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice
- (2013) V. K. Bhat et al. DIABETOLOGIA
- Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery
- (2013) L. Sjöström JOURNAL OF INTERNAL MEDICINE
- Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
- (2013) B. Finan et al. Science Translational Medicine
- Action and therapeutic potential of oxyntomodulin
- (2013) Alessandro Pocai Molecular Metabolism
- Unraveling oxyntomodulin, GLP1's enigmatic brother
- (2012) Alessandro Pocai JOURNAL OF ENDOCRINOLOGY
- The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis
- (2010) D. Singh-Franco et al. DIABETES OBESITY & METABOLISM
- Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass
- (2009) J Korner et al. INTERNATIONAL JOURNAL OF OBESITY
- Control of food intake and energy expenditure by amylin—therapeutic implications
- (2009) T A Lutz INTERNATIONAL JOURNAL OF OBESITY
- Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity
- (2008) S. R. Smith et al. DIABETES CARE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search